“Figuring out a good, comfortable way to bring that [ED] conversation up…will really pay dividends in other parts of the health care system. It will also allow more people to appropriately get funneled to urology to better address it,” says Denise Asafu-Adjei, MD, MPH.
In this video, Denise Asafu-Adjei, MD, MPH, discusses the importance of patient counseling and inquiry regarding erectile dysfunction, as it will pave the way for discovering larger medical conditions that may otherwise go unnoticed. Asafu-Adjei is a urologist and medical director of male reproductive medicine at Loyola University, Chicago, Illinois.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.